Contineum prices $110M IPO as IPF and neuro drugs advance

2024-04-04

IPO临床2期

Another San Diego biotech will go public Friday morning, with Contineum Therapeutics making its Nasdaq debut to fund its Phase 2 neuro drug and early-stage work in fibrosis and other areas.

Contineum $CTNM raised $110 million in its offering. The startup priced at the low end of the $16 to $18 range it proposed on Monday and sold fewer shares than originally planned, at 6.87 million versus 8.8 million. Its share price was down about 10% shortly after it started trading.

Contineum prices $110M IPO as IPF and neuro drugs advance

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构